Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | USP9X | Q93008 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | RRM1 | P23921 | 3/20 | 0.32 |
| ▸ | RRM2B | Q7LG56 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596408 | 0.87 | GRIN1 (0.33) | USP9X | |
| SCHEMBL596185 | 0.86 | GRM4 (0.34) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL10285792 | 0.85 | S1PR1 (0.33) | AKT1PIK3CA | |
| SCHEMBL595395 | 0.84 | PSEN1 (0.34) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL595686 | 0.83 | PSEN1 (0.38) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL596591 | 0.82 | GRM4 (0.33) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL595995 | 0.81 | KMT2A (0.40) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL595782 | 0.81 | GRM2 (0.35) | PIK3CACHRM2CHRM1RRM1RRM2B | |
| SCHEMBL596892 | 0.80 | — | — | |
| SCHEMBL596519 | 0.79 | EED (0.31) | EEDRBBP4SUZ12EZH2AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1867636-A1 | PYRIDYLMETHYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | APP, IAPP, BACE1 | AKT1 2582/4885PIK3CA 4787/4885USP9X 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.